Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.

Fu X, Jeselsohn R, Pereira R, Hollingsworth EF, Creighton CJ, Li F, Shea M, Nardone A, De Angelis C, Heiser LM, Anur P, Wang N, Grasso CS, Spellman PT, Griffith OL, Tsimelzon A, Gutierrez C, Huang S, Edwards DP, Trivedi MV, Rimawi MF, Lopez-Terrada D, Hilsenbeck SG, Gray JW, Brown M, Osborne CK, Schiff R.

Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):E6600-E6609. Epub 2016 Oct 6.

2.

Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6.

Yamaguchi N, Nakayama Y, Yamaguchi N.

J Biol Chem. 2017 May 19;292(20):8136-8148. doi: 10.1074/jbc.M116.763276. Epub 2017 Mar 7.

3.

Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients.

Ijichi N, Shigekawa T, Ikeda K, Horie-Inoue K, Shimizu C, Saji S, Aogi K, Tsuda H, Osaki A, Saeki T, Inoue S.

Horm Cancer. 2012 Aug;3(4):147-59. doi: 10.1007/s12672-012-0111-0. Epub 2012 Apr 3.

PMID:
22476979
4.

Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas.

Droog M, Nevedomskaya E, Kim Y, Severson T, Flach KD, Opdam M, Schuurman K, Gradowska P, Hauptmann M, Dackus G, Hollema H, Mourits M, Nederlof P, van Boven H, Linn SC, Wessels L, van Leeuwen FE, Zwart W.

Cancer Res. 2016 Jul 1;76(13):3773-84. doi: 10.1158/0008-5472.CAN-14-1813. Epub 2016 May 6. Erratum in: Cancer Res. 2018 May 1;78(9):2446.

5.

FOXA1 is a key determinant of estrogen receptor function and endocrine response.

Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS.

Nat Genet. 2011 Jan;43(1):27-33. doi: 10.1038/ng.730. Epub 2010 Dec 12.

6.

More on FOX News: FOXA1 on the horizon of estrogen receptor function and endocrine response.

Fu X, Huang C, Schiff R.

Breast Cancer Res. 2011 Apr 20;13(2):307. doi: 10.1186/bcr2849.

7.

Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer.

Wright TM, Wardell SE, Jasper JS, Stice JP, Safi R, Nelson ER, McDonnell DP.

Mol Cancer Res. 2014 Dec;12(12):1829-39. doi: 10.1158/1541-7786.MCR-14-0195. Epub 2014 Aug 6.

8.

FOXA1 is an independent prognostic marker for ER-positive breast cancer.

Mehta RJ, Jain RK, Leung S, Choo J, Nielsen T, Huntsman D, Nakshatri H, Badve S.

Breast Cancer Res Treat. 2012 Feb;131(3):881-90. doi: 10.1007/s10549-011-1482-6. Epub 2011 Apr 19.

PMID:
21503684
9.

A transcriptional complex composed of ER(α), GATA3, FOXA1 and ELL3 regulates IL-20 expression in breast cancer cells.

Lee JY, Park YJ, Oh N, Kwack KB, Park KS.

Oncotarget. 2017 Jun 27;8(26):42752-42760. doi: 10.18632/oncotarget.17459.

10.

Bisphenol A stimulates the epithelial mesenchymal transition of estrogen negative breast cancer cells via FOXA1 signals.

Zhang XL, Wang HS, Liu N, Ge LC.

Arch Biochem Biophys. 2015 Nov 1;585:10-16. doi: 10.1016/j.abb.2015.09.006. Epub 2015 Sep 9.

PMID:
26363213
11.

KLF4 overcomes tamoxifen resistance by suppressing MAPK signaling pathway and predicts good prognosis in breast cancer.

Jia Y, Zhou J, Luo X, Chen M, Chen Y, Wang J, Xiong H, Ying X, Hu W, Zhao W, Deng W, Wang L.

Cell Signal. 2018 Jan;42:165-175. doi: 10.1016/j.cellsig.2017.09.025. Epub 2017 Oct 4.

PMID:
28988130
12.

FOXA1 represses the molecular phenotype of basal breast cancer cells.

Bernardo GM, Bebek G, Ginther CL, Sizemore ST, Lozada KL, Miedler JD, Anderson LA, Godwin AK, Abdul-Karim FW, Slamon DJ, Keri RA.

Oncogene. 2013 Jan 31;32(5):554-63. doi: 10.1038/onc.2012.62. Epub 2012 Mar 5.

13.

Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions.

Wen J, Li R, Lu Y, Shupnik MA.

Oncogene. 2009 Jan 29;28(4):575-86. doi: 10.1038/onc.2008.405. Epub 2008 Nov 10.

14.

Differential oestrogen receptor binding is associated with clinical outcome in breast cancer.

Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, Brown GD, Gojis O, Ellis IO, Green AR, Ali S, Chin SF, Palmieri C, Caldas C, Carroll JS.

Nature. 2012 Jan 4;481(7381):389-93. doi: 10.1038/nature10730.

15.

Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.

Barone I, Brusco L, Gu G, Selever J, Beyer A, Covington KR, Tsimelzon A, Wang T, Hilsenbeck SG, Chamness GC, Andò S, Fuqua SA.

J Natl Cancer Inst. 2011 Apr 6;103(7):538-52. doi: 10.1093/jnci/djr058. Epub 2011 Mar 29.

16.

Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis.

Bergamaschi A, Christensen BL, Katzenellenbogen BS.

Breast Cancer Res. 2011 Jun 29;13(3):R70. doi: 10.1186/bcr2913.

17.

FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer.

Wolf I, Bose S, Williamson EA, Miller CW, Karlan BY, Koeffler HP.

Int J Cancer. 2007 Mar 1;120(5):1013-22.

18.

HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance.

Jin K, Park S, Teo WW, Korangath P, Cho SS, Yoshida T, Győrffy B, Goswami CP, Nakshatri H, Cruz LA, Zhou W, Ji H, Su Y, Ekram M, Wu Z, Zhu T, Polyak K, Sukumar S.

Cancer Discov. 2015 Sep;5(9):944-59. doi: 10.1158/2159-8290.CD-15-0090. Epub 2015 Jul 15.

19.

FOXA1 is essential for aryl hydrocarbon receptor-dependent regulation of cyclin G2.

Ahmed S, Al-Saigh S, Matthews J.

Mol Cancer Res. 2012 May;10(5):636-48. doi: 10.1158/1541-7786.MCR-11-0502.

20.

TNFα signaling exposes latent estrogen receptor binding sites to alter the breast cancer cell transcriptome.

Franco HL, Nagari A, Kraus WL.

Mol Cell. 2015 Apr 2;58(1):21-34. doi: 10.1016/j.molcel.2015.02.001. Epub 2015 Mar 5.

Supplemental Content

Support Center